No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.1x · 10Y median 60.1x · 3rd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T21:47:58.071Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Rani Therapeutics Holdings, Inc. (RANI) stock was $0.83 as of Oct 6, 2026, 4:00 PM EDT, up 6.96% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +53.1% · 3-year avg -27.0%/yr · 5-year avg -46.7%/yr
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration.
Biotechnology · San Jose, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.05
Revenue Est.
$1.28M
Last Quarter Results
EPS
$-0.04
vs Estimate
$-0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RANI | $54.14M | $0.83 | +6.96% | +53.13% | -46.70% | N/A | N/A |
| 2NMAD | $53.70M | $4.34 | +8.22% | N/A | N/A | N/A | vs RANI |
| 3ALDX | $55.25M | $0.92 | -0.84% | -83.77% | -36.54% | -18.91% | vs RANI |
| 4MDAI | $52.83M | $1.66 | -1.78% | -24.11% | -29.57% | N/A | vs RANI |
| 5ZYBT | $52.60M | $1.11 | -6.72% | -55.42% | N/A | N/A | vs RANI |
| 6OKYO | $56.02M | $1.46 | -0.68% | -28.18% | N/A | N/A | vs RANI |
forward FY estimate
N/A
$1.71M
vs Estimate
$925000.00
Consensus Rating
Based on 5 analysts
Average Price Target
$7.20
+768.7% upside
Low
$5.00
Current
$0.83
High
$11.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 2 |
| Quarter ending Dec 2026 | $-0.05 | $-0.05 | $-0.05 | 2 |
| Quarter ending Mar 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Quarter ending Jun 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.21 | $-0.17 | $-0.11 | 2 |
| FY 2027 | $-0.23 | $-0.19 | $-0.12 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.28M | $1.28M | $1.28M | 2 |
| Quarter ending Dec 2026 | $1.57M | $1.57M | $1.57M | 2 |
| Quarter ending Mar 2027 | $4.60M | $4.60M | $4.60M | 1 |
| Quarter ending Jun 2027 | $4.80M | $4.80M | $4.80M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.56M | $6.26M | $7.30M | 3 |
| FY 2027 | $4.83M | $6.63M | $7.73M | 3 |
